메뉴 건너뛰기




Volumn 20, Issue 12, 2010, Pages 1627-1651

Diabetes area participation analysis: A review of companies and targets described in the 2008 2010 patent literature

Author keywords

; ; 11 HSD1; ACC; AMPK; DGAT1; diabetes mellitus; GK; GLP1R; GPR119; GPR40; GPR81; Kv1.3; participation analysis; patent activity; PPAR ; SCD1; SGLT2

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE 1; ANTHRACENE DERIVATIVE; ANTIDIABETIC AGENT; AR 231453; BENZIMIDAZOLE DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIPEPTIDYL PEPTIDASE IV; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; GLUCOKINASE; INCB 13739; NEUROPEPTIDE Y RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHLORIZIN; PIOGLITAZONE; POTASSIUM CHANNEL KV1.3; REMOGLIFLOZIN ETABONATE; RETINOL BINDING PROTEIN 4; RO 4389620; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SOMATOSTATIN; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 78649283638     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.533171     Document Type: Review
Times cited : (44)

References (169)
  • 1
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary
    • Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28(1):88-126
    • (2007) Eur Heart J , vol.28 , Issue.1 , pp. 88-126
    • Ryden, L.1    Standl, E.2    Bartnik, M.3
  • 2
    • 77955657267 scopus 로고    scopus 로고
    • Insulin resistance lipotoxicity type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009
    • DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53(7):1270-87
    • (2010) Diabetologia , vol.53 , Issue.7 , pp. 1270-87
    • Defronzo, R.A.1
  • 3
    • 54749114466 scopus 로고    scopus 로고
    • It's not how fat you are, it's what you do with it that counts
    • Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008;6(9):1819-23
    • (2008) PLoS Biol , vol.6 , Issue.9 , pp. 1819-23
    • Virtue, S.1    Vidal-Puig, A.2
  • 4
    • 19944366619 scopus 로고    scopus 로고
    • Regulation of plasma triglycerides in insulin resistance and diabetes
    • Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36(3):232-40
    • (2005) Arch Med Res , vol.36 , Issue.3 , pp. 232-40
    • Ginsberg, H.N.1    Zhang, Y.L.2    Hernandez-Ono, A.3
  • 6
    • 43449108812 scopus 로고    scopus 로고
    • Economic costs of diabetes in the U.S. in 2007
    • Anonymous
    • Anonymous. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31(3):596-615
    • (2008) Diabetes Care , vol.31 , Issue.3 , pp. 596-615
  • 7
    • 77649156851 scopus 로고    scopus 로고
    • Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus
    • Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123(3A):S12-18
    • (2010) Am J Med , vol.123 , Issue.3 A
    • Blonde, L.1
  • 8
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
    • Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
    • (2006) N Engl J Med , vol.355 , Issue.23 , pp. 2427-43
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3
  • 9
    • 77949833491 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD ADVANCE VADT UKPDS PROactive and NICE-SUGAR
    • Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010;160(1-2):8-19
    • (2010) Wien Med Wochenschr , vol.160 , Issue.1-2 , pp. 8-19
    • Schernthaner, G.1
  • 10
    • 78649308905 scopus 로고    scopus 로고
    • Available from [Cited]
    • Charlish P. 2010. Available from: http://www. scripclinicalresearch.com/ therapeutics/Diabetes-sector-continues-to-generate-immense-interest-297521? autnRef=/contentstore/gcpj/codex/b61e1963-79ed-11df-870a-bbcce1c03e31.xml [Cited]
    • (2010)
    • Charlish, P.1
  • 13
    • 65349177200 scopus 로고    scopus 로고
    • AMPK: An emerging drug target for diabetes and the metabolic syndrome
    • Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9(5):407-16
    • (2009) Cell Metab , vol.9 , Issue.5 , pp. 407-16
    • Zhang, B.B.1    Zhou, G.2    Li, C.3
  • 14
    • 78649261863 scopus 로고    scopus 로고
    • Merck Sharp & Dohme Corp.; Metabasis Therapeutics Inc. WO2010051176
    • Merck Sharp & Dohme Corp.; Metabasis Therapeutics, Inc. WO2010051176; 2010
    • (2010)
  • 15
    • 78649250581 scopus 로고    scopus 로고
    • Merck Sharp & Dohme Corp. WO2010047982
    • Merck Sharp & Dohme Corp. WO2010047982; 2010
    • (2010)
  • 16
    • 78649299830 scopus 로고    scopus 로고
    • TransTech Pharma Inc. 2009111700
    • TransTech Pharma, Inc. 2009111700; 2009
    • (2009)
  • 17
    • 78649263678 scopus 로고    scopus 로고
    • Astellas Pharma Inc. WO2009041521
    • Astellas Pharma, Inc. WO2009041521; 2009
    • (2009)
  • 18
    • 78649308463 scopus 로고    scopus 로고
    • Pfizer Inc WO2008084300
    • Pfizer, Inc. WO2008084300. 2008
    • (2008)
  • 19
    • 78649295730 scopus 로고    scopus 로고
    • F. Hoffman-La Roche AG. US2008300279
    • F. Hoffman-La Roche AG. US2008300279; 2008
    • (2008)
  • 20
    • 78649291452 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2008074692
    • F. Hoffmann-La Roche AG. WO2008074692; 2008
    • (2008)
  • 21
    • 78649274790 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. US2009270505
    • F. Hoffmann-La Roche AG. US2009270505; 2009
    • (2009)
  • 22
    • 78649304584 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2009270500
    • F. Hoffmann-La Roche AG. WO2009270500; 2009
    • (2009)
  • 23
    • 78649237300 scopus 로고    scopus 로고
    • Sirtris Pharmaceuticals Inc. WO2010019606
    • Sirtris Pharmaceuticals, Inc. WO2010019606; 2010
    • (2010)
  • 24
    • 36248975293 scopus 로고    scopus 로고
    • SIRT1 transgenic mice show phenotypes resembling calorie restriction
    • Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007;6(6):759-67
    • (2007) Aging Cell , vol.6 , Issue.6 , pp. 759-67
    • Bordone, L.1    Cohen, D.2    Robinson, A.3
  • 25
    • 78649255306 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2008003611
    • F. Hoffmann-La Roche AG. WO2008003611; 2008
    • (2008)
  • 26
    • 78649307617 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2009132986
    • F. Hoffmann-La Roche AG. WO2009132986; 2009
    • (2009)
  • 27
    • 78649251506 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2010006940
    • F. Hoffmann-La Roche AG. WO2010006940; 2010
    • (2010)
  • 28
    • 78649273068 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. US2008293756
    • F. Hoffmann-La Roche AG. US2008293756; 2008
    • (2008)
  • 29
    • 78649243548 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2008037628
    • F. Hoffmann-La Roche AG. WO2008037628; 2008
    • (2008)
  • 30
    • 78649283580 scopus 로고    scopus 로고
    • F. Hoffmann-La Roche AG. WO2010052144
    • F. Hoffmann-La Roche AG. WO2010052144; 2010
    • (2010)
  • 31
    • 12244288887 scopus 로고    scopus 로고
    • Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin
    • Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90(1):359-65
    • (2005) J Clin Endocrinol Metab , vol.90 , Issue.1 , pp. 359-65
    • Korner, J.1    Bessler, M.2    Cirilo, L.J.3
  • 32
    • 78649311675 scopus 로고    scopus 로고
    • Merck Sharp & Dohme Corp WO2010053830
    • Merck Sharp & Dohme Corp. WO2010053830; 2010
    • (2010)
  • 33
    • 46749086605 scopus 로고    scopus 로고
    • Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors
    • Wolkenberg SE, Thut CJ. Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors. Curr Opin Drug Discov Devel 2008;11(4):446-57
    • (2008) Curr Opin Drug Discov Devel , vol.11 , Issue.4 , pp. 446-57
    • Wolkenberg, S.E.1    Thut, C.J.2
  • 34
    • 78649314535 scopus 로고    scopus 로고
    • Merck & Co., Inc. WO2008051272
    • Merck & Co., Inc. WO2008051272; 2008
    • (2008)
  • 35
    • 78649309767 scopus 로고    scopus 로고
    • Merck & Co., Inc. WO2009011836
    • Merck & Co., Inc. WO2009011836; 2009
    • (2009)
  • 36
    • 78649232775 scopus 로고    scopus 로고
    • Merck Sharp & Dohme Corp. WO2010056717
    • Merck Sharp & Dohme Corp. WO2010056717; 2010
    • (2010)
  • 37
    • 78649287443 scopus 로고    scopus 로고
    • Merck & Co., Inc. US2009131451
    • Merck & Co., Inc. US2009131451; 2009
    • (2009)
  • 38
    • 78649276085 scopus 로고    scopus 로고
    • Merck & Co., Inc.; Banyu Pharmaceutical Co. Ltd. WO2008088692
    • Merck & Co., Inc.; Banyu Pharmaceutical Co. Ltd. WO2008088692; 2008
    • (2008)
  • 39
    • 78649240314 scopus 로고    scopus 로고
    • Merck & Co., Inc. WO2008039327
    • Merck & Co., Inc. WO2008039327; 2008
    • (2008)
  • 40
    • 78649260982 scopus 로고    scopus 로고
    • Banyu Pharmaceutical Co., Ltd. WO2009038021
    • Banyu Pharmaceutical Co., Ltd. WO2009038021; 2009
    • (2009)
  • 41
    • 78649311674 scopus 로고    scopus 로고
    • Merck Frosst Canada Ltd. WO2010025553
    • Merck Frosst Canada Ltd. WO2010025553; 2010
    • (2010)
  • 42
    • 72249113143 scopus 로고    scopus 로고
    • Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)
    • Leger S, Black WC, Deschenes D, et al. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett 2010;20(2):499-502
    • (2010) Bioorg Med Chem Lett , vol.20 , Issue.2 , pp. 499-502
    • Leger, S.1    Black, W.C.2    Deschenes, D.3
  • 43
    • 78649306294 scopus 로고    scopus 로고
    • Medicinal Chemistry Gordon Conference. Available from [Cited]
    • Medicinal Chemistry Gordon Conference. Available from: http://www. grc.org/programs.aspx? year=2010&program=medchem [Cited]
  • 44
    • 48749112588 scopus 로고    scopus 로고
    • Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
    • Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38(7-8):778-801
    • (2008) Xenobiotica , vol.38 , Issue.7-8 , pp. 778-801
    • Hagenbuch, B.1    Gui, C.2
  • 45
    • 78649255788 scopus 로고    scopus 로고
    • Merck Frosst Canada Ltd. WO2008046226
    • Merck Frosst Canada Ltd. WO2008046226; 2008
    • (2008)
  • 46
    • 78649253539 scopus 로고    scopus 로고
    • Merck Frosst Canada Ltd. WO2009073973
    • Merck Frosst Canada Ltd. WO2009073973; 2009
    • (2009)
  • 47
    • 78649246908 scopus 로고    scopus 로고
    • Merck Frosst Canada Ltd. WO2009012573
    • Merck Frosst Canada Ltd. WO2009012573; 2009
    • (2009)
  • 48
    • 77649192401 scopus 로고    scopus 로고
    • Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6
    • Shimamura K, Nagumo A, Miyamoto Y et al. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. Eur J Pharmacol 2010;630(1-3):34-41
    • (2010) Eur J Pharmacol , vol.630 , Issue.1-3 , pp. 34-41
    • Shimamura, K.1    Nagumo, A.2    Miyamoto, Y.3
  • 49
    • 0034773404 scopus 로고    scopus 로고
    • Role of AMP-activated protein kinase in mechanism of metformin action
    • Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167-74
    • (2001) J Clin Invest , vol.108 , Issue.8 , pp. 1167-74
    • Zhou, G.1    Myers, R.2    Li, Y.3
  • 51
    • 78649299829 scopus 로고    scopus 로고
    • Wyeth John and Brother Ltd US2009163474
    • Wyeth, John, and Brother Ltd. US2009163474; 2009
    • (2009)
  • 52
    • 78649292739 scopus 로고    scopus 로고
    • Pfizer Inc WO2010013161
    • Pfizer, Inc. WO2010013161; 2010
    • (2010)
  • 53
    • 62749205848 scopus 로고    scopus 로고
    • The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
    • Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab 2008;34(6 Pt 2):685-91
    • (2008) Diabetes Metab , vol.34 , Issue.6 PART 2 , pp. 685-91
    • Cariou, B.1
  • 54
    • 78649300670 scopus 로고    scopus 로고
    • Wyeth John and Brother Ltd WO2008100627
    • Wyeth, John, and Brother Ltd. WO2008100627; 2008
    • (2008)
  • 56
    • 78649278151 scopus 로고    scopus 로고
    • Sanofi-Aventis Deutschland G.m.b.H. WO2008006496
    • Sanofi-Aventis Deutschland G.m.b.H. WO2008006496; 2008
    • (2008)
  • 57
    • 78649241273 scopus 로고    scopus 로고
    • Sanofi-Aventis Deutschland G.m.b.H. WO2010043566
    • Sanofi-Aventis Deutschland G.m.b.H. WO2010043566; 2010
    • (2010)
  • 58
    • 78649306760 scopus 로고    scopus 로고
    • Sanofi-Aventis. WO2009149820
    • Sanofi-Aventis. WO2009149820; 2009
    • (2009)
  • 59
    • 78649286536 scopus 로고    scopus 로고
    • Sanofi-Aventis. WO2008000950
    • Sanofi-Aventis. WO2008000950; 2008
    • (2008)
  • 60
    • 78649278152 scopus 로고    scopus 로고
    • Sanofi-Aventis. WO2008135141
    • Sanofi-Aventis. WO2008135141; 2008
    • (2008)
  • 61
    • 78649244420 scopus 로고    scopus 로고
    • Sanofi-Aventis. EP2023144
    • Sanofi-Aventis. EP2023144; 2009
    • (2009)
  • 62
    • 78649313667 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008121592
    • Takeda Pharmaceutical Co. Ltd. WO2008121592; 2008
    • (2008)
  • 63
    • 78649296169 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008136428
    • Takeda Pharmaceutical Co. Ltd. WO2008136428; 2008
    • (2008)
  • 64
    • 78649231907 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008011131
    • Takeda Pharmaceutical Co. Ltd. WO2008011131; 2008
    • (2008)
  • 65
    • 78649270780 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008067465
    • Takeda Pharmaceutical Co. Ltd. WO2008067465; 2008
    • (2008)
  • 66
    • 78649274380 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008001931
    • Takeda Pharmaceutical Co. Ltd. WO2008001931; 2008
    • (2008)
  • 67
    • 78649251024 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008044767
    • Takeda Pharmaceutical Co. Ltd. WO2008044767; 2008
    • (2008)
  • 68
    • 78649255304 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2009110520
    • Takeda Pharmaceutical Co. Ltd. WO2009110520; 2009
    • (2009)
  • 69
    • 78649244839 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2009057784
    • Takeda Pharmaceutical Co. Ltd. WO2009057784; 2009
    • (2009)
  • 70
    • 78649240313 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008143262
    • Takeda Pharmaceutical Co. Ltd. WO2008143262; 2008
    • (2008)
  • 71
    • 78649254849 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2010001869
    • Takeda Pharmaceutical Co. Ltd. WO2010001869; 2010
    • (2010)
  • 72
    • 78649238994 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008016131
    • Takeda Pharmaceutical Co. Ltd. WO2008016131; 2008
    • (2008)
  • 73
    • 78649242119 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2008010511
    • Takeda Pharmaceutical Co. Ltd. WO2008010511; 2008
    • (2008)
  • 74
    • 78649273066 scopus 로고    scopus 로고
    • Takeda Pharmaceutical Co. Ltd. WO2009145286
    • Takeda Pharmaceutical Co. Ltd. WO2009145286; 2009
    • (2009)
  • 75
    • 33745325873 scopus 로고    scopus 로고
    • Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling
    • Imoto K, Kukidome D, Nishikawa T, et al. Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling. Diabetes 2006;55(5):1197-204
    • (2006) Diabetes , vol.55 , Issue.5 , pp. 1197-204
    • Imoto, K.1    Kukidome, D.2    Nishikawa, T.3
  • 76
    • 1542357667 scopus 로고    scopus 로고
    • The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity
    • Xu J, Wang P, Li Y, et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004;101(9):3112-17
    • (2004) Proc Natl Acad Sci USA , vol.101 , Issue.9 , pp. 3112-17
    • Xu, J.1    Wang, P.2    Li, Y.3
  • 77
    • 78649294386 scopus 로고    scopus 로고
    • Bionomics Ltd. WO2008040057
    • Bionomics Ltd. WO2008040057; 2008
    • (2008)
  • 78
    • 78649307167 scopus 로고    scopus 로고
    • Bionomics Ltd. WO2009043117
    • Bionomics Ltd. WO2009043117; 2009
    • (2009)
  • 79
    • 78649299417 scopus 로고    scopus 로고
    • Arena Pharmaceuticals Inc.; Merck & Co. WO2010030360
    • Arena Pharmaceuticals, Inc.; Merck & Co. WO2010030360; 2010
    • (2010)
  • 80
    • 24744448667 scopus 로고    scopus 로고
    • Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal
    • Abu-Elheiga L, Matzuk MM, Kordari P, et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA 2005;102(34):12011-16
    • (2005) Proc Natl Acad Sci USA , vol.102 , Issue.34 , pp. 12011-16
    • Abu-Elheiga, L.1    Matzuk, M.M.2    Kordari, P.3
  • 81
    • 33744781581 scopus 로고    scopus 로고
    • Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis
    • Mao J, DeMayo FJ, Li H, et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA 2006;103(22):8552-7
    • (2006) Proc Natl Acad Sci USA , vol.103 , Issue.22 , pp. 8552-7
    • Mao, J.1    Demayo, F.J.2    Li, H.3
  • 82
    • 33644654777 scopus 로고    scopus 로고
    • Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
    • Savage DB, Choi CS, Samuel VT, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116(3):817-24
    • (2006) J Clin Invest , vol.116 , Issue.3 , pp. 817-24
    • Savage, D.B.1    Choi, C.S.2    Samuel, V.T.3
  • 83
    • 0035970805 scopus 로고    scopus 로고
    • Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
    • Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001;291(5513):2613-16
    • (2001) Science , vol.291 , Issue.5513 , pp. 2613-16
    • Abu-Elheiga, L.1    Matzuk, M.M.2    Abo-Hashema, K.A.3    Wakil, S.J.4
  • 84
    • 0042337449 scopus 로고    scopus 로고
    • Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets
    • Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high- carbohydrate diets. Proc Natl Acad Sci USA 2003;100(18):10207-12
    • (2003) Proc Natl Acad Sci USA , vol.100 , Issue.18 , pp. 10207-12
    • Abu-Elheiga, L.1    Oh, W.2    Kordari, P.3    Wakil, S.J.4
  • 85
    • 36749052873 scopus 로고    scopus 로고
    • Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity
    • Choi CS, Savage DB, Abu-Elheiga L, et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 2007;104(42):16480-5
    • (2007) Proc Natl Acad Sci USA , vol.104 , Issue.42 , pp. 16480-5
    • Choi, C.S.1    Savage, D.B.2    Abu-Elheiga, L.3
  • 86
    • 13444265891 scopus 로고    scopus 로고
    • Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice
    • Oh W, Abu-Elheiga L, Kordari P, et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc Natl Acad Sci USA 2005;102(5):1384-9
    • (2005) Proc Natl Acad Sci USA , vol.102 , Issue.5 , pp. 1384-9
    • Oh, W.1    Abu-Elheiga, L.2    Kordari, P.3
  • 87
    • 72649089588 scopus 로고    scopus 로고
    • Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity
    • Hoehn KL, Turner N, Swarbrick MM, et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab 2010;11(1):70-6
    • (2010) Cell Metab , vol.11 , Issue.1 , pp. 70-6
    • Hoehn, K.L.1    Turner, N.2    Swarbrick, M.M.3
  • 88
    • 77952213776 scopus 로고    scopus 로고
    • Gene knockout of Acc2 has little effect on body weight fat mass or food intake
    • Olson DP, Pulinilkunnil T, Cline GW, et al. Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc Natl Acad Sci USA 2010;107(16):7598-603
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.16 , pp. 7598-603
    • Olson, D.P.1    Pulinilkunnil, T.2    Cline, G.W.3
  • 89
    • 50549202600 scopus 로고
    • The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
    • Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1(7285):785-9
    • (1963) Lancet , vol.1 , Issue.7285 , pp. 785-9
    • Randle, P.J.1    Garland, P.B.2    Hales, C.N.3    Newsholme, E.A.4
  • 90
    • 0141510051 scopus 로고    scopus 로고
    • Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis and increase fatty acid oxidation in cultured cells and in experimental animals
    • Harwood HJ Jr, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003;278(39):37099-111
    • (2003) J Biol Chem , vol.278 , Issue.39 , pp. 37099-111
    • Harwood Jr., H.J.1    Petras, S.F.2    Shelly, L.D.3
  • 91
    • 67650462508 scopus 로고    scopus 로고
    • Review of recent acetyl-CoA carboxylase inhibitor patents: Mid-2007-2008
    • Corbett JW. Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008. Expert Opin Ther Pat 2009;19(7):943-56
    • (2009) Expert Opin Ther Pat , vol.19 , Issue.7 , pp. 943-56
    • Corbett, J.W.1
  • 92
    • 0025341608 scopus 로고
    • The mechanism by which rat liver glucokinase is inhibited by the regulatory protein
    • Vandercammen A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990;191(2):483-9
    • (1990) Eur J Biochem , vol.191 , Issue.2 , pp. 483-9
    • Vandercammen, A.1    Van Schaftingen, E.2
  • 93
    • 0031851588 scopus 로고    scopus 로고
    • The physiological role of glucokinase binding and translocation in hepatocytes
    • Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998;38:303-31
    • (1998) Adv Enzyme Regul , vol.38 , pp. 303-31
    • Agius, L.1
  • 94
    • 67349139275 scopus 로고    scopus 로고
    • Assessing the potential of glucokinase activators in diabetes therapy
    • Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8(5):399-416
    • (2009) Nat Rev Drug Discov , vol.8 , Issue.5 , pp. 399-416
    • Matschinsky, F.M.1
  • 95
    • 0024342083 scopus 로고
    • Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans
    • Iynedjian PB, Pilot PR, Nouspikel T, et al. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci USA 1989;86(20):7838-42
    • (1989) Proc Natl Acad Sci USA , vol.86 , Issue.20 , pp. 7838-42
    • Iynedjian, P.B.1    Pilot, P.R.2    Nouspikel, T.3
  • 96
    • 0036303140 scopus 로고    scopus 로고
    • Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons
    • Dunn-Meynell AA, Routh VH, Kang L, et al. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 2002;51(7):2056-65
    • (2002) Diabetes , vol.51 , Issue.7 , pp. 2056-65
    • Dunn-Meynell, A.A.1    Routh, V.H.2    Kang, L.3
  • 97
    • 56449093424 scopus 로고    scopus 로고
    • Glucose sensing in L cells: A primary cell study
    • Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab 2008;8(6):532-9
    • (2008) Cell Metab , vol.8 , Issue.6 , pp. 532-9
    • Reimann, F.1    Habib, A.M.2    Tolhurst, G.3
  • 98
    • 49649099805 scopus 로고    scopus 로고
    • Glucokinase and molecular aspects of liver glycogen metabolism
    • Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414(1):1-18
    • (2008) Biochem J , vol.414 , Issue.1 , pp. 1-18
    • Agius, L.1
  • 99
    • 0035787576 scopus 로고    scopus 로고
    • Cell-specific roles of glucokinase in glucose homeostasis
    • Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Rec Prog Horm Res 2001;56:195-217
    • (2001) Rec Prog Horm Res , vol.56 , pp. 195-217
    • Postic, C.1    Shiota, M.2    Magnuson, M.A.3
  • 100
    • 70350741368 scopus 로고    scopus 로고
    • Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia
    • Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30(11):1512-26
    • (2009) Hum Mutat , vol.30 , Issue.11 , pp. 1512-26
    • Osbak, K.K.1    Colclough, K.2    Saint-Martin, C.3
  • 101
    • 0037624071 scopus 로고    scopus 로고
    • Allosteric activators of glucokinase: Potential role in diabetes therapy
    • Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301(5631):370-3
    • (2003) Science , vol.301 , Issue.5631 , pp. 370-3
    • Grimsby, J.1    Sarabu, R.2    Corbett, W.L.3
  • 102
    • 78049512890 scopus 로고    scopus 로고
    • Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: A mechanistic study
    • Available at
    • Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95(11). Available at http://jcem.endojournals.org/cgi/reprint/jc.2010-1041v1
    • (2010) J Clin Endocrinol Metab , vol.95 , Issue.11
    • Bonadonna, R.C.1    Heise, T.2    Arbet-Engels, C.3
  • 103
  • 104
    • 0037838892 scopus 로고    scopus 로고
    • The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids
    • Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003;278(13):11303-11
    • (2003) J Biol Chem , vol.278 , Issue.13 , pp. 11303-11
    • Briscoe, C.P.1    Tadayyon, M.2    Andrews, J.L.3
  • 105
    • 0037434991 scopus 로고    scopus 로고
    • Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40
    • Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173-6
    • (2003) Nature , vol.422 , Issue.6928 , pp. 173-6
    • Itoh, Y.1    Kawamata, Y.2    Harada, M.3
  • 106
    • 33846327180 scopus 로고    scopus 로고
    • GPR40 is expressed in glucagon producing cells and affects glucagon secretion
    • Flodgren E, Olde B, Meidute-Abaraviciene S, et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007;354(1):240-5
    • (2007) Biochem Biophys Res Commun , vol.354 , Issue.1 , pp. 240-5
    • Flodgren, E.1    Olde, B.2    Meidute-Abaraviciene, S.3
  • 107
    • 20944433543 scopus 로고    scopus 로고
    • The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse
    • Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1(4):245-58
    • (2005) Cell Metab , vol.1 , Issue.4 , pp. 245-58
    • Steneberg, P.1    Rubins, N.2    Bartoov-Shifman, R.3
  • 108
    • 33745607930 scopus 로고    scopus 로고
    • Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules
    • Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 2006;148(5):619-28
    • (2006) Br J Pharmacol , vol.148 , Issue.5 , pp. 619-28
    • Briscoe, C.P.1    Peat, A.J.2    McKeown, S.C.3
  • 109
    • 53849146735 scopus 로고    scopus 로고
    • The long-chain fatty acid receptor GPR40, and glucolipotoxicity: Investigations using GPR40-knockout mice
    • Brownlie R, Mayers RM, Pierce JA, et al. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem Soc Trans 2008;36(Pt 5):950-4
    • (2008) Biochem Soc Trans , vol.36 , Issue.PART 5 , pp. 950-4
    • Brownlie, R.1    Mayers, R.M.2    Pierce, J.A.3
  • 110
    • 34047177401 scopus 로고    scopus 로고
    • GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo
    • Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007;56(4):1087-94
    • (2007) Diabetes , vol.56 , Issue.4 , pp. 1087-94
    • Latour, M.G.1    Alquier, T.2    Oseid, E.3
  • 111
    • 50949128408 scopus 로고    scopus 로고
    • Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice
    • Tan CP, Feng Y, Zhou YP, et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008;57(8):2211-19
    • (2008) Diabetes , vol.57 , Issue.8 , pp. 2211-19
    • Tan, C.P.1    Feng, Y.2    Zhou, Y.P.3
  • 112
    • 52249093427 scopus 로고    scopus 로고
    • The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding
    • Kebede M, Alquier T, Latour MG, et al. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57(9):2432-7
    • (2008) Diabetes , vol.57 , Issue.9 , pp. 2432-7
    • Kebede, M.1    Alquier, T.2    Latour, M.G.3
  • 113
    • 65549096659 scopus 로고    scopus 로고
    • Poitout V. GPR40: Good cop, bad cop?
    • Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2009;58(5):1035-6
    • (2009) Diabetes , vol.58 , Issue.5 , pp. 1035-6
    • Alquier, T.1
  • 114
    • 65549114432 scopus 로고    scopus 로고
    • Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice
    • Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58(5):1067-76
    • (2009) Diabetes , vol.58 , Issue.5 , pp. 1067-76
    • Nagasumi, K.1    Esaki, R.2    Iwachidow, K.3
  • 115
    • 67649331670 scopus 로고    scopus 로고
    • Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): An emerging target for type 2 diabetes
    • Bharate SB, Nemmani KVS, Vishwakarma RA. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin Ther Pat 2009;19(2):237-64
    • (2009) Expert Opin Ther Pat , vol.19 , Issue.2 , pp. 237-64
    • Bharate, S.B.1    Kvs, N.2    Vishwakarma, R.A.3
  • 116
    • 10644275303 scopus 로고    scopus 로고
    • Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor
    • Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326(4):744-51
    • (2005) Biochem Biophys Res Commun , vol.326 , Issue.4 , pp. 744-51
    • Soga, T.1    Ohishi, T.2    Matsui, T.3
  • 117
    • 33644627958 scopus 로고    scopus 로고
    • Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents
    • Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3(3):167-75
    • (2006) Cell Metab , vol.3 , Issue.3 , pp. 167-75
    • Overton, H.A.1    Babbs, A.J.2    Doel, S.M.3
  • 118
    • 34248527678 scopus 로고    scopus 로고
    • A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release
    • Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148(6):2601-9
    • (2007) Endocrinology , vol.148 , Issue.6 , pp. 2601-9
    • Chu, Z.L.1    Jones, R.M.2    He, H.3
  • 119
    • 51849099001 scopus 로고    scopus 로고
    • Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119
    • Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 2008;51(17):5172-5
    • (2008) J Med Chem , vol.51 , Issue.17 , pp. 5172-5
    • Semple, G.1    Fioravanti, B.2    Pereira, G.3
  • 120
    • 52749098923 scopus 로고    scopus 로고
    • Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion
    • Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57(9):2280-7
    • (2008) Diabetes , vol.57 , Issue.9 , pp. 2280-7
    • Edfalk, S.1    Steneberg, P.2    Edlund, H.3
  • 121
    • 67649913243 scopus 로고    scopus 로고
    • GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
    • Lan H, Vassileva G, Corona A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009;201(2):219-30
    • (2009) J Endocrinol , vol.201 , Issue.2 , pp. 219-30
    • Lan, H.1    Vassileva, G.2    Corona, A.3
  • 122
    • 42449126696 scopus 로고    scopus 로고
    • A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release
    • Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008;149(5):2038-47
    • (2008) Endocrinology , vol.149 , Issue.5 , pp. 2038-47
    • Chu, Z.L.1    Carroll, C.2    Alfonso, J.3
  • 123
    • 65549142522 scopus 로고    scopus 로고
    • GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell
    • Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009;58(5):1058-66
    • (2009) Diabetes , vol.58 , Issue.5 , pp. 1058-66
    • Lauffer, L.M.1    Iakoubov, R.2    Brubaker, P.L.3
  • 124
    • 58149464981 scopus 로고    scopus 로고
    • Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    • Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009;52(2):289-98
    • (2009) Diabetologia , vol.52 , Issue.2 , pp. 289-98
    • Parker, H.E.1    Habib, A.M.2    Rogers, G.J.3
  • 126
    • 85047683614 scopus 로고    scopus 로고
    • Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action
    • Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142(4):1371-6
    • (2001) Endocrinology , vol.142 , Issue.4 , pp. 1371-6
    • Seckl, J.R.1    Walker, B.R.2
  • 127
    • 73249141243 scopus 로고    scopus 로고
    • 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation
    • Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94(12):4645-54
    • (2009) J Clin Endocrinol Metab , vol.94 , Issue.12 , pp. 4645-54
    • Cooper, M.S.1    Stewart, P.M.2
  • 128
    • 0026095840 scopus 로고
    • The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization
    • Tannin GM, Agarwal AK, Monder C, et al. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991;266(25):16653-8
    • (1991) J Biol Chem , vol.266 , Issue.25 , pp. 16653-8
    • Tannin, G.M.1    Agarwal, A.K.2    Monder, C.3
  • 129
    • 0030936556 scopus 로고    scopus 로고
    • Does central obesity reflect "cushing's disease of the omentum"?
    • Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349(9060):1210-13
    • (1997) Lancet , vol.349 , Issue.9060 , pp. 1210-13
    • Bujalska, I.J.1    Kumar, S.2    Stewart, P.M.3
  • 130
    • 0027159080 scopus 로고
    • Human placental 11 beta-hydroxysteroid dehydrogenase: Evidence for and partial purification of a distinct NAD-dependent isoform
    • Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 1993;132(6):2614-21
    • (1993) Endocrinology , vol.132 , Issue.6 , pp. 2614-21
    • Brown, R.W.1    Chapman, K.E.2    Edwards, C.R.3    Seckl, J.R.4
  • 131
    • 0024445143 scopus 로고
    • The kidney is the major site of cortisone production in man
    • Whitworth JA, Stewart PM, Burt D, et al. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989;31(3):355-61
    • (1989) Clin Endocrinol (Oxf) , vol.31 , Issue.3 , pp. 355-61
    • Whitworth, J.A.1    Stewart, P.M.2    Burt, D.3
  • 132
    • 0028034209 scopus 로고
    • Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme
    • Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994;105(2):R11-17
    • (1994) Mol Cell Endocrinol , vol.105 , Issue.2
    • Albiston, A.L.1    Obeyesekere, V.R.2    Smith, R.E.3    Krozowski, Z.S.4
  • 133
    • 0035051205 scopus 로고    scopus 로고
    • Tissue-specific dysregulation of cortisol metabolism in human obesity
    • Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86(3):1418-21
    • (2001) J Clin Endocrinol Metab , vol.86 , Issue.3 , pp. 1418-21
    • Rask, E.1    Olsson, T.2    Soderberg, S.3
  • 134
    • 0035824440 scopus 로고    scopus 로고
    • A transgenic model of visceral obesity and the metabolic syndrome
    • Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294(5549):2166-70
    • (2001) Science , vol.294 , Issue.5549 , pp. 2166-70
    • Masuzaki, H.1    Paterson, J.2    Shinyama, H.3
  • 135
    • 0031283178 scopus 로고    scopus 로고
    • 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
    • Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94(26):14924-9
    • (1997) Proc Natl Acad Sci USA , vol.94 , Issue.26 , pp. 14924-9
    • Kotelevtsev, Y.1    Holmes, M.C.2    Burchell, A.3
  • 136
    • 0035798621 scopus 로고    scopus 로고
    • Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice
    • Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276(44):41293-300
    • (2001) J Biol Chem , vol.276 , Issue.44 , pp. 41293-300
    • Morton, N.M.1    Holmes, M.C.2    Fievet, C.3
  • 137
    • 0036882136 scopus 로고    scopus 로고
    • Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity
    • Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002;87(12):5630-5
    • (2002) J Clin Endocrinol Metab , vol.87 , Issue.12 , pp. 5630-5
    • Tomlinson, J.W.1    Sinha, B.2    Bujalska, I.3
  • 138
    • 42149162795 scopus 로고    scopus 로고
    • 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity
    • Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008;17(4):481-96
    • (2008) Expert Opin Investig Drugs , vol.17 , Issue.4 , pp. 481-96
    • Hughes, K.A.1    Webster, S.P.2    Walker, B.R.3
  • 139
    • 0036432995 scopus 로고    scopus 로고
    • Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
    • Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45(11):1528-32
    • (2002) Diabetologia , vol.45 , Issue.11 , pp. 1528-32
    • Alberts, P.1    Engblom, L.2    Edling, N.3
  • 140
    • 0242468543 scopus 로고    scopus 로고
    • Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains
    • Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144(11):4755-62
    • (2003) Endocrinology , vol.144 , Issue.11 , pp. 4755-62
    • Alberts, P.1    Nilsson, C.2    Selen, G.3
  • 141
    • 2342510149 scopus 로고    scopus 로고
    • Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice
    • Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;101(18):7088-93
    • (2004) Proc Natl Acad Sci USA , vol.101 , Issue.18 , pp. 7088-93
    • Paterson, J.M.1    Morton, N.M.2    Fievet, C.3
  • 142
    • 77955590502 scopus 로고    scopus 로고
    • 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
    • Morgan SA, Tomlinson JW. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19(9):1067-76
    • (2010) Expert Opin Investig Drugs , vol.19 , Issue.9 , pp. 1067-76
    • Morgan, S.A.1    Tomlinson, J.W.2
  • 143
    • 0037238379 scopus 로고    scopus 로고
    • Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes
    • Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88(1):285-91
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.1 , pp. 285-91
    • Andrews, R.C.1    Rooyackers, O.2    Walker, B.R.3
  • 144
    • 0028839840 scopus 로고
    • Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation
    • Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80(11):3155-9
    • (1995) J Clin Endocrinol Metab , vol.80 , Issue.11 , pp. 3155-9
    • Walker, B.R.1    Connacher, A.A.2    Lindsay, R.M.3
  • 146
    • 77955836270 scopus 로고    scopus 로고
    • 17beta-Hydroxysteroid dehydrogenase inhibitors: A patent review
    • Poirier D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 2010;20(9):1123-45
    • (2010) Expert Opin Ther Pat , vol.20 , Issue.9 , pp. 1123-45
    • Poirier, D.1
  • 147
    • 0037143752 scopus 로고    scopus 로고
    • Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity
    • Ntambi JM, Miyazaki M, Stoehr JP, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002;99(17):11482-6
    • (2002) Proc Natl Acad Sci USA , vol.99 , Issue.17 , pp. 11482-6
    • Ntambi, J.M.1    Miyazaki, M.2    Stoehr, J.P.3
  • 148
    • 0141813781 scopus 로고    scopus 로고
    • Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle
    • Rahman SM, Dobrzyn A, Dobrzyn P, et al. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc Natl Acad Sci USA 2003;100(19):11110-15
    • (2003) Proc Natl Acad Sci USA , vol.100 , Issue.19 , pp. 11110-15
    • Rahman, S.M.1    Dobrzyn, A.2    Dobrzyn, P.3
  • 149
    • 12144268751 scopus 로고    scopus 로고
    • Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue
    • Rahman SM, Dobrzyn A, Lee SH, et al. Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am J Physiol Endocrinol Metab 2005;288(2):E381-7
    • (2005) Am J Physiol Endocrinol Metab , vol.288 , Issue.2
    • Rahman, S.M.1    Dobrzyn, A.2    Lee, S.H.3
  • 150
    • 4644340815 scopus 로고    scopus 로고
    • Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment
    • Lee SH, Dobrzyn A, Dobrzyn P, et al. Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment. J Lipid Res 2004;45(9):1674-82
    • (2004) J Lipid Res , vol.45 , Issue.9 , pp. 1674-82
    • Lee, S.H.1    Dobrzyn, A.2    Dobrzyn, P.3
  • 151
    • 34047269605 scopus 로고    scopus 로고
    • Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat
    • Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J Biol Chem 2007;282(4):2483-93
    • (2007) J Biol Chem , vol.282 , Issue.4 , pp. 2483-93
    • Sampath, H.1    Miyazaki, M.2    Dobrzyn, A.3    Ntambi, J.M.4
  • 152
    • 63249121641 scopus 로고    scopus 로고
    • Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver
    • Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009;58(1):203-8
    • (2009) Diabetes , vol.58 , Issue.1 , pp. 203-8
    • Kotronen, A.1    Seppanen-Laakso, T.2    Westerbacka, J.3
  • 153
    • 64049110523 scopus 로고    scopus 로고
    • Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis
    • Arendt BM, Mohammed SS, Aghdassi E, et al. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 2009;139(4):691-5
    • (2009) J Nutr , vol.139 , Issue.4 , pp. 691-5
    • Arendt, B.M.1    Mohammed, S.S.2    Aghdassi, E.3
  • 154
    • 41149102818 scopus 로고    scopus 로고
    • Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans
    • Stefan N, Peter A, Cegan A, et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008;51(4):648-56
    • (2008) Diabetologia , vol.51 , Issue.4 , pp. 648-56
    • Stefan, N.1    Peter, A.2    Cegan, A.3
  • 155
    • 78649242535 scopus 로고    scopus 로고
    • Glenmark Pharmaceuticals S.A. WO2010035052
    • Glenmark Pharmaceuticals, S.A. WO2010035052; 2010
    • (2010)
  • 156
    • 64749094872 scopus 로고
    • Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose
    • Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30(2):125-9
    • (1951) J Clin Invest , vol.30 , Issue.2 , pp. 125-9
    • Farber, S.J.1    Berger, E.Y.2    Earle, D.P.3
  • 157
    • 0028044629 scopus 로고
    • The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose
    • Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93(1):397-404
    • (1994) J Clin Invest , vol.93 , Issue.1 , pp. 397-404
    • Kanai, Y.1    Lee, W.S.2    You, G.3
  • 158
    • 0034997336 scopus 로고    scopus 로고
    • Renal Na(+)-glucose cotransporters
    • Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-18
    • (2001) Am J Physiol Renal Physiol , vol.280 , Issue.1
    • Wright, E.M.1
  • 159
    • 0036937335 scopus 로고    scopus 로고
    • Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)
    • Van Den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002;111(6):544-7
    • (2002) Hum Genet , vol.111 , Issue.6 , pp. 544-7
    • Van Den Heuvel, L.P.1    Assink, K.2    Willemsen, M.3    Monnens, L.4
  • 160
    • 10744229025 scopus 로고    scopus 로고
    • Molecular analysis of the SGLT2 gene in patients with renal glucosuria
    • Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14(11):2873-82
    • (2003) J Am Soc Nephrol , vol.14 , Issue.11 , pp. 2873-82
    • Santer, R.1    Kinner, M.2    Lassen, C.L.3
  • 161
    • 1142263153 scopus 로고    scopus 로고
    • Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria
    • Calado J, Soto K, Clemente C, et al. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 2004;114(3):314-16
    • (2004) Hum Genet , vol.114 , Issue.3 , pp. 314-16
    • Calado, J.1    Soto, K.2    Clemente, C.3
  • 163
    • 0023275573 scopus 로고
    • Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
    • Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15
    • (1987) J Clin Invest , vol.79 , Issue.5 , pp. 1510-15
    • Rossetti, L.1    Smith, D.2    Shulman, G.I.3
  • 164
    • 0032850016 scopus 로고    scopus 로고
    • T-1095, an inhibitor of renal Na +-glucose cotransporters, may provide a novel approach to treating diabetes
    • Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48(9):1794-800
    • (1999) Diabetes , vol.48 , Issue.9 , pp. 1794-800
    • Oku, A.1    Ueta, K.2    Arakawa, K.3
  • 165
    • 33845873376 scopus 로고    scopus 로고
    • Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
    • Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30
    • (2007) J Pharmacol Exp Ther , vol.320 , Issue.1 , pp. 323-30
    • Katsuno, K.1    Fujimori, Y.2    Takemura, Y.3
  • 166
    • 64549093267 scopus 로고    scopus 로고
    • Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
    • Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609(1-3):148-54
    • (2009) Eur J Pharmacol , vol.609 , Issue.1-3 , pp. 148-54
    • Fujimori, Y.1    Katsuno, K.2    Ojima, K.3
  • 167
    • 52649083832 scopus 로고    scopus 로고
    • Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
    • Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327(1):268-76
    • (2008) J Pharmacol Exp Ther , vol.327 , Issue.1 , pp. 268-76
    • Fujimori, Y.1    Katsuno, K.2    Nakashima, I.3
  • 168
    • 77953734934 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus
    • Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;50(6):623-35
    • (2010) J Clin Pharmacol , vol.50 , Issue.6 , pp. 623-35
    • Hussey, E.K.1    Clark, R.V.2    Amin, D.M.3
  • 169
    • 74949093195 scopus 로고    scopus 로고
    • Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
    • Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009;19(11):1485-99
    • (2009) Expert Opin Ther Pat , vol.19 , Issue.11 , pp. 1485-99
    • Washburn, W.N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.